Clinical variable | No response | Response | OR (95% CI)a | |
---|---|---|---|---|
N (%) | 54 (34.4) | 103 (65.6) | – | |
Age (year) | 34.7 ± 14.7 | 34.3 ± 15.3 | 1.005 (0.98–1.03) | |
Gender (male %) | 37 (68.5) | 60 (58.3) | 0.62 (0.31–1.27) | |
MAP (mmHg) | 95.4 ± 16.5 | 92.7 ± 11.9 | 1.02 (0.99–1.04) | |
BMI (kg/m2) | 24.4 ± 3.7 | 23.7 ± 3.7 | 1.04 (0.94–1.14) | |
Ln(Pro) (g/24 h) | 1.8 ± 0.4 | 1.8 ± 0.4 | 1.17 (0.52–2.60) | |
Albumin (g/L) | 16.5 ± 6.8 | 16.1 ± 5.6 | 1.01 (0.96–1.07) | |
eGFR (mL/min/1.73 m2) | 81.9 ± 37.5 | 99.1 ± 27.5 | 0.98 (0.97–0.99)# | |
TG (mmol/L) | 4.3 ± 3.9 | 3.6 ± 3.4 | 1.05 (0.96–1.16) | |
TC (mmol/L) | 10.6 ± 3.6 | 10.5 ± 4.1 | 1.001 (0.92–1.09) | |
Ln(β2-MG/uCr) (ug/mmoL) | 4.6 ± 1.7 | 3.2 ± 1.5 | 1.76 (1.30–2.37)# |
Pathological evaluation | Score | No response | Response | OR (95% CI) |
---|---|---|---|---|
FSGS (%) | 46 (45.5) | 55 (54.5) | 5.02(2.16–11.7)# | |
MCD (%) | 8 (14.3) | 48 (85.7) | 0.20(0.09–0.46)# | |
Global sclerosis (%) | 0 | 27 (50.0) | 74 (71.8) | -ref- |
1 | 23 (42.6) | 28 (27.2) | 2.25(1.11–4.56)* | |
Segmental sclerosis (%) | 0 | 10 (18.5) | 59 (57.3) | -ref- |
1 | 40 (74.1) | 43 (41.7) | 5.49(2.47–12.17)# | |
Interstitial fibrosis (%) | 0 | 8 (14.8) | 43 (35.0) | -ref- |
1 | 42 (77.8) | 59 (57.3) | 3.83(1.63–8.97)# | |
Inflammatory cell infiltration (%) | 0 | 14 (25.9) | 47 (45.6) | -ref- |
1 | 36 (66.7) | 55 (53.4) | 2.20(1.06-–4.56)* | |
Tubular atrophy (%) | 0 | 12 (22.2) | 46 (44.7) | -ref- |
1 | 38 (70.4) | 56 (54.4) | 2.60(1.22–5.55)* | |
Vascular lesion (%) | 0 | 29 (53.7) | 62 (60.2) | -ref- |
1 | 20 (37.0) | 40 (38.8) | 1.07 (0.53–2.14) |